 Home > Medical News > Medicines Company News > The 5th domestic Ruckus Pharma capecitabine tablet was approved for production and deemed to have been reviewed

The 5th domestic Ruckus Pharma capecitabine tablet was approved for production and deemed to have been reviewed

 Last Update: 2022-02-19
 Source: Internet
 Author: User

Tags

emperor chinese food

average hair growth year

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On January 20, the official website of the State Food and Drug Administration showed that Nanjing Rucko Pharma’s Class 4 generic capecitabine tablets were approved for production and deemed to have been reviewed, making it the fifth domestically-produced company to be approved
.
According to data from Minet.
com, the terminal sales of this product in China's public medical institutions will exceed 3 billion yuan in 2020
.

　Source: State Food and Drug Administration official website

Capecitabine is an oral fluoropyrimidine carbamate antitumor drug developed by Roche for the treatment of colorectal cancer and breast cancer
.

Including the original manufacturer, there are currently 6 domestic companies that have the production approval for capecitabine tablets
.
According to data from Minet.
com, the terminal sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) will exceed 3 billion yuan in 2020
.
Affected by centralized procurement, sales in the first half of 2021 fell by more than 50% year-on-year
.

　　In China's urban physical pharmacy terminals, it is predicted that the sales growth rate of capecitabine tablets in 2021 will exceed 100%
.

　　Sales of oral antineoplastic drugs in physical pharmacies in cities in China (unit: ten thousand yuan)

　　Source: Competitive landscape of physical pharmacy terminals in Chinese cities

　　In recent years, the sales scale of oral anti -tumor drugs in physical pharmacy terminals in urban China has continued to expand, and the sales growth rate has remained at double digits.
It is expected that the year-on-year growth in 2021 will exceed 20% .

　　2020 Top 5 products of oral anti-tumor drugs in Chinese urban physical pharmacies

　　Source: Minet.
com China's urban physical pharmacy terminal competition pattern

　　In terms of product rankings, the total market share of the TOP5 oral anti-tumor drug products in urban physical pharmacies in China will be close to 40% in 2020, including AstraZeneca's osimertinib, Chia Tai Tianqing's anlotinib and Hansoh's alometinib Sales rose rapidly
.

　　Source: Minet database, the official website of the State Food and Drug Administration, etc.

　　Note: Minet.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 urban physical pharmacies in cities and above (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
The statistics are as of January 20.
If there are any omissions, please correct me!

　Source: State Food and Drug Administration official website

　　Capecitabine is an oral fluoropyrimidine carbamate antitumor drug developed by Roche for the treatment of colorectal cancer and breast cancer
.